Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Damon Race: Can Gene Therapy Deliver Durable Expression Over Time?
May 15, 2026, 03:32

Damon Race: Can Gene Therapy Deliver Durable Expression Over Time?

Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared on LinkedIn:

”The first generation of hemophilia A gene therapies changed the field in an important way.

The question is no longer simply whether gene therapy can reduce bleeding.

The question is whether gene therapy can deliver durable expression over time.

Patients remain highly interested in gene therapy, but long-term durability has become central to adoption decisions for both patients and providers.

At GeneVentiv, this understanding shaped the design and program development of GENV-HEM (AAV8.FVa), which leverages native hepatic biology associated with Factor V expression.

Importantly, our vision for the future of hemophilia A gene therapy includes inhibitor patients.

Patient decisions to adopt gene therapy will ultimately be made not just by efficacy, but by durability.”

Damon Race: Can Gene Therapy Deliver Durable Expression Over Time?

Stay updated with Hemostasis Today.